Cefoperazone for the Treatment of Acute Urinary Tract Infection: Multicentered Comparative and N oncomparative Studies

Two separate multicentered studies evaluated the efficacy and safety of cefoperazone for the therapy of patients with acute bacterial urinary tract infections. A noncompara-tive study involved 198 patients, 114 of whom were evaluated for efficacy of the drug. Satisfactory clinical responses occurred in 890,10 of the patients. The primary pathogen was eliminated during therapy in 91 % of infections, including 60 of 61 involving Escherichia coli, 13 of 19 involving Pseudomonas aeruginosa, 5 of 5 involving Strepto-coccus jaecalis, and 32 of 39 involving other bacteria. Adverse reactions possibly re-lated to therapy with cefoperazone included diarrhea in 5 % of patients, rash in 1 %, and pain at the site of injection in 2%. In a multicentered comparative study in which patients were randomly assigned to treatment groups, 58 evaluable patients were treated with cefoperazone and 49 were treated with a comparative agent (25 with cefa-mandole and 24 with an aminoglycoside). Satisfactory clinical responses occurred in 100 % of those given cefoperazone and in 97 % of those given a comparative agent. The primary pathogen was eradicated during therapy in 87 % of those treated with cefopera-zone and in 95 % of those treated with a comparative agent (88 % of those given a